Skip to main content
logo
Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.7020
+0.0854 (13.85%)
At close: Jun 26, 2026, 4:00 PM EDT
0.7400
+0.0380 (5.41%)
After-hours: Jun 26, 2026, 7:59 PM EDT

Vistagen Therapeutics Revenue

In the fiscal year ending March 31, 2026, Vistagen Therapeutics had annual revenue of $1.27M with 161.11% growth. Vistagen Therapeutics had revenue of $383.50K in the quarter ending March 31, 2026, with 250.23% growth.

Revenue (ttm)
$1.27M
Revenue Growth
+161.11%
P/S Ratio
22.70
Revenue / Employee
$30,951
Employees
41
Market Cap
28.80M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Mar 31, 20261.27M783.00K161.11%
Mar 31, 2025486.00K-578.00K-54.32%
Mar 31, 20241.06M1.29M-
Mar 31, 2023-227.00K-1.34M-
Mar 31, 20221.11M19.40K1.78%
Mar 31, 20211.09M--
Mar 31, 2020---
Mar 31, 2019---
Mar 31, 2018---
Mar 31, 20171.25M--
Mar 31, 2016---
Mar 31, 2015---
Mar 31, 2014---
Mar 31, 2013200.40K-1.14M-85.07%
Mar 31, 20121.34M-728.80K-35.19%
Mar 31, 20112.07M--
Dec 31, 2010---
Dec 31, 2009---
Dec 31, 2008---
Dec 31, 2007---

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Evaxion7.53M
Dyadic International3.81M
IGC Pharma1.11M
Pluri1.08M
Serina Therapeutics130.00K
Neuphoria Therapeutics-13.27K
Revenue Rankings

VTGN News

More News